Resources from the same session
5378 - 2nd/3rd-line Nivolumab vs Nivo plus Ipilimumab in Malignant Pleural Mesothelioma: long-term results of IFCT-1501 MAPS2 phase 2R trial with a focus on hyperprogression (HPD)
Presenter: Gerard Zalcman
Session: Proffered Paper 2 – Non-metastatic NSCLC and other thoracic malignancies (mesothelioma and thymic carcinoma)
Resources:
Abstract
Slides
Webcast
3080 - Mutational profile of malignant pleural mesothelioma (MPM) in the phase II RAMES Study
Presenter: Maria Pagano
Session: Proffered Paper 2 – Non-metastatic NSCLC and other thoracic malignancies (mesothelioma and thymic carcinoma)
Resources:
Abstract
1316 - SAKK 17/16: Lurbinectedin as second or third line palliative chemotherapy in malignant pleural mesothelioma (MPM): A multi-center, single-arm Phase II trial.
Presenter: Yannis Metaxas
Session: Proffered Paper 2 – Non-metastatic NSCLC and other thoracic malignancies (mesothelioma and thymic carcinoma)
Resources:
Abstract
Slides
Webcast
803 - Durable anti-tumor activity of the multi-targeted inhibitor lenvatinib in patients with advanced or metastatic thymic carcinoma; Preliminary results from a multicenter phase II (REMORA) trial.
Presenter: Shoichi Itoh
Session: Proffered Paper 2 – Non-metastatic NSCLC and other thoracic malignancies (mesothelioma and thymic carcinoma)
Resources:
Abstract
Slides
Webcast
1665 - A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM) – results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
Presenter: Sanjay Popat
Session: Proffered Paper 2 – Non-metastatic NSCLC and other thoracic malignancies (mesothelioma and thymic carcinoma)
Resources:
Abstract
Slides
Webcast
Proffered Paper 2 – Non-metastatic NSCLC and other thoracic malignancies (mesothelioma and thymic carcinoma) - Invited Discussant 1843O and 1844O
Presenter: Paul Baas
Session: Proffered Paper 2 – Non-metastatic NSCLC and other thoracic malignancies (mesothelioma and thymic carcinoma)
Resources:
Slides
Webcast